ArticleMolecular biology reports2025
Evaluation of the effects of Theranekron and Sorafenib treatments on alpha-fetoprotein, heat shock protein 90 alpha and indoleamine 2,3 dioxygenase 1 enzyme levels in experimental hepatocellular carcinoma in rats.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the most common type of primary liver cancer and one of the leading causes of cancer-related deaths worldwide. Early diagnosis of HCC, as well as the identification of biomarkers that can help determine the effectiveness of applied treatments, is extremely important. In the present study, the effects of Theranekron (TCAE, Tarantula cubensis alcoholic extract) and Sorafenib (S) on plasma and liver tissue levels of alpha-fetoprotein (AFP), heat shock protein 90 alpha (HSP90α), and indoleamine 2,3-dioxygenase 1 (IDO1) were investigated in Wistar-Albino rats with experimentally induced HCC using diethylnitrosamine (DEN) and n-nitrosomorpholine (nMOR).
methodsThe study included a total of 58 rats divided into 7 groups: Healthy Group (HG, n = 6), HG + TCAE (HGT, n = 6), HG + Sorafenib (HGS, n = 6), HCC Control (HC, n = 10), HCC + TCAE (HT, n = 10), HCC + Sorafenib (HS, n = 10), and HCC + TCAE + Sorafenib (HTS, n = 10).
resultsPlasma and liver AFP, HSP90α, and IDO1 levels were found to be significantly elevated in the HC group compared with the healthy control groups (p < 0.001). Administration of Theranekron and Sorafenib, either alone or in combination, resulted in significant reductions in AFP, HSP90α, and IDO1 levels, particularly in plasma (p < 0.001). Furthermore, histopathological evaluation revealed that Theranekron and Sorafenib treatments exhibited less tumorigenic morphology compared with the HC group.
conclusionTaken together, these results demonstrate that Theranekron enhances the antitumor efficacy of Sorafenib. Moreover, HSP90α and IDO1 levels appear to provide higher specificity and sensitivity, suggesting their potential as more reliable biomarkers for monitoring tumor prognosis.
Indexed as
Identifiers
41148449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.